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In the presence of glucose the protein hexokinase 2 (Hxk2p), normally
resident in the cytosol, is translocated to the nucleus where it impairs the
activation of transcription of the glucose-repressed genes HXK1, GLK1
and SUC2, and promotes the activation of transcription of the glucose-
induced genes HXK2 and HXT1. Here, we demonstrate the involvement
of an heptameric motif, named the MED8 site, in the direct binding of
the mediator protein Med8p, either as a monomer or as a homodimer.
Because this site was previously involved in the Hxk2p-dependent
glucose-induced regulation of gene transcription, we tested whether
Hxk2p interacts with Med8p. Our results show that Hxk2 and Med8
proteins are physically associated and that this Hxk2p–Med8p interaction
is of physiological signiﬁcance because both proteins have been found
interacting together in a cluster with DNA fragments containing the
MED8 site. We conclude that Hxk2p operates through the MED8 site, by
interacting with Med8p, in the glucose signal transduction pathway of
Saccharomyces cerevisiae.
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Introduction
Glucose regulates carbon utilization in Saccharo-
myces cerevisiae mainly by inhibiting or activating
the transcription of numerous genes. The genes
affected include among others those involved in
gluconeogenesis, the glyoxylate and Krebs cycle,
respiration, and in the utilization of alternative
carbon sources.
1–3 This mechanism, called glucose
repression, ensures the use of glucose in preference
to other carbon sources. Glucose also induces
expression of genes required for its own utilization,
like the genes encoding several glycolytic enzymes
and glucose transporters.
4 Although several of the
genes implicated in the pathways that control
glucose repression and induction have been identi-
ﬁed a complete mechanistic picture of the phenom-
enon is not yet available. In particular the position
of each factor in the signalling cascade and the
interactions among them are still not well known.
One central component of the glucose sensing
pathway seems to be the hexokinase 2 protein
(Hxk2p), that in addition to its classical metabolic
role in glucose phosphorylation at C6, plays a role
in glucose repression and activation signalling as
a transcriptional regulator.
5,6 If indeed Hxk2p
plays a role as a transcriptional regulator, one
should expect that, at least under certain con-
ditions, the enzyme will be present in the nucleus.
Several results with different approaches support
such a localization.
7,8 In addition, it has been
shown that a nuclear localization of the Hxk2 pro-
tein is required for glucose repression of SUC2,
HXK1 and GLK1, and that the nuclear Hxk2p is
involved in the formation of speciﬁc DNA–protein
complexes during glucose-dependent repression of
these genes.
6,8
Recently, looking for new factors required for
expression of SUC2i nS. cerevisiae, a protein called
Med8p was identiﬁed. Med8p speciﬁcally binds to
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the HXK2 gene and to the upstream activating
sequences (UASs) of the SUC2 gene.
9,10 Med8p
was shown to constitute a component of a large
multiprotein complex called Srb/mediator com-
plex. The latter enhances basal transcription and
facilitates activated transcription by interacting
with the C-terminal domain (CTD) of RNA poly-
merase II.
11–13 The transcription cofactors, as
Med8p, mediate access to genes in chromatin and
they help to establish, maintain or activate regulat-
ory networks. Thus, a possible role of Med8p could
be to affect the formation and activity of basal
initiation complexes by linking speciﬁc DNA–
protein regulatory complexes to the RNA polymer-
ase II holoenzyme transcriptional machinery.
Here, we demonstrate that Med8p binds to DNA
both as a monomer and as a homodimer through a
heptameric sequence designated “MED8 site”. We
also demonstrate that Hxk2p interacts speciﬁcally
with Med8p both in vivo and in vitro. Furthermore,
we map the interacting domains of both proteins
and describe a role for the carboxy-terminal
domains of Hxk2p and Med8p in this interaction.
These results suggest a possible model of how
Hxk2p is involved in glucose signalling.
Results
Med8p binds to an heptameric motif present in
several glucose-regulated genes
Med8p binds to cis-acting elements present in
regulatory regions of many glucose-repressed and
induced genes. Previous results with different
approaches support the notion that Med8p binds
to the SUC2 and HXK2 regulatory region through
the heptameric motif, (C/A)(G/A)GAAAT.
9,10
Interestingly, as can be seen in Figure 1, gel-
mobility shift analysis has demonstrated that
Med8p also binds to regulatory regions of the
HXT1, GLK1 and HXK1 promoters through
sequences containing a UASSUC-like heptameric
motif with the consensus sequence: (C/A)
(G/A)(G/A) AAAT. Thus, we designate this
sequence as the “MED8 site”. Among all these
genes, HXT1 and HXK2, are induced,
4,14 whereas
GLK1, HXK1 and SUC2 are repressed by high
glucose levels.
14,15
Hxk2p participates in DNA–protein complexes
with cis-acting regulatory elements of the SUC2
gene, which contain the heptameric motif
(C/A)(G/A)GAAAT.
8 The sequences of both DRSs
in the HXK2 gene includes the DNA motives,
CGGAAAT and AAGAAAT,
16 which show a per-
fect match with those in the UAS element of SUC2
gene.
15 Moreover, gel-mobility shift analysis
demonstrated that Hxk2p-mediated regulation of
HXK1 and GLK1 is exerted through MED8 regulat-
ory sequences present in the promoters of these
genes.
6 These results suggest that both Hxk2p and
Med8p function through the MED8 site. To gain
further insight into Hxk2p and Med8p function,
we have investigated the interactions between
these proteins.
Interaction of Hxk2p with Med8p
Although Hxk2 and Med8 proteins form part of
the same DNA–protein complex with a regulatory
element of the SUC2 promoter,
8–10 an interaction
between both proteins has not yet been demon-
strated. To study this possibility, we have used a
yeast two-hybrid system to detect if Hxk2p inter-
acts with a Gal4p DNA-binding domain (GBD)
Figure 1. Gel-mobility shift
analysis of Med8p binding to the
regulatory regions of the HXT1,
HXK1 and GLK1 promoters at
sequences containing the MED8
site. Each reaction included 0.5 ng
of [
32P]MED8HXT1 ((a), lanes 1 to 3),
[
32P]- MED8HXK1 ((b), lanes 4 to 6)
or [
32P]MED8GLK1 ((c), lanes 7 to 9)
as DNA probe and, except for
lanes 1, 4 and 7, 6 ml( 3 mg) of
Med8p puriﬁed protein were
added. Med8p was obtained from
GST-Med8 fusion protein coupled
to glutathione-Sepharose beads by
site-speciﬁc separation of the GST
afﬁnity tag using 2.5 units of
thrombin. The competitor for bind-
ing was 20 ng (lanes 3, 6 and 9) of
the corresponding unlabelled
MED8 annealed oligonucleotides.
Nucleoprotein complexes were
resolved from free DNA by non-denaturing PAGE. F, Unbound fragment; CI, position of shifted band observed with
puriﬁed Med8p.
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encoding the full-length Med8 protein or truncated
versions of this protein were fused to GAL4 DNA-
binding domains. Each of the pGBKT7-MED8
fusion plasmids was co-transformed with a plas-
mid expressing a fusion of GAL4 activation domain
with Hxk2p or a plasmid expressing a fusion of the
GAL4 activation domain with Med8p into an
appropriate reporter strain. The interaction
between Hxk2–Med8, Med8–Med8 and Hxk2–
Hxk2 proteins was monitored by b-galactosidase
expression levels, with a ﬁlter assay and a liquid-
culture assay.
As shown in Figure 2, only the full-length
Med8p gave a strong interaction with Hxk2p. The
strength of the interaction obtained with two-
hybrid approaches could be affected by factors
others than the binding afﬁnity of the protein
pairs in question. This is exempliﬁed by the
variation in the strength of the signal obtained
when a given pair of interacting proteins is
exchanged between GAD and GBD. However, in
our study such variation in b-galactosidase activity
was not detected when Hxk2p and Med8p were
exchanged between GAD and GBD. This result
suggests that the strength of the signals obtained
is mainly due to binding afﬁnity of the Hxk2p–
Med8p pair.
Med8 protein has a leucine zipper motif between
amino acid residues 69 and 90 which can work as a
protein interaction domain that allows proteins to
either hetero- or homodimerize.
17 To attempt to
resolve whether this protein is part of a monomer
or a homodimer we have used the two-hybrid
assay approach. When paired with itself, full-
length Med8p gave a weak interaction (Figure 2).
To provide a positive control assay for these
results, we extended the analysis to the Hxk2p–
Hxk2p pair, for which homodimerization has been
reported.
18–20 As can be seen in Figure 2, the results
obtained conﬁrmed the ability of Hxk2p to interact
with itself to form a homodimer.
Figure 2. Two-hybrid interaction of Hxk2p with Med8p and analysis of dimer formation of Hxk2p and Med8p. Yeast
two-hybrid assay of full-length and fragmented Med8 protein interactions with Hxk2p and Med8p. Partials
(Med8p-C10, aa 1–213; Med8p-C47, aa 1–176 and Med8p-C63, aa 1–160) and full-length (Med8p, aa 1–223) Med8p
fused to the Gal4p binding domain (GBD) were individually co-transformed into yeast strain Y187 with constructs
encoding the Gal4p activation domain alone (GAD), GAD fused to full-length (Hxk2p, aa 1–485) Hxk2p or full-length
(Med8p, aa 1–223) Med8p, as indicated. Yeast two-hybrid assay of full-length and partial Hxk2p interactions with
Hxk2p and Med8p. Partial (Hxk2-C70, aa 1–416) and full-length (Hxk2p, aa 1–485) Hxk2p fused to the GBD were
individually co-transformed into yeast strain Y187 with constructs encoding the Gal4p activation domain alone
(GAD), GAD fused to full-length (Hxk2p, aa 1–485) Hxk2p or full-length (Med8p, aa 1–223) Med8p, as indicated.
Protein–protein interactions were examined in each transformant by the qualitative and quantitative assay methods
for b-galactosidase activity. Closed bars, blue colony colour; open bars, white colony colour. The values are the
averages of b-galactosidase activity for three transformants. Each measured value was within 30% of the average.
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involved in the interaction
Med8p contains various motifs such as a
C-terminal serine/threonine-rich motif, a basic
motif and a leucine zipper motif as indicated in
Figure 2.
21 Subfragments of Med8p were fused to
the Gal4p DNA-binding domain and tested for
interaction with Hxk2p and Med8p by two-hybrid
assays to identify the domains of Med8p that are
important for interaction with these proteins. We
detected no interaction between Hxk2p and any
Med8p truncated derivative (Figure 2). Identical
results were obtained when we analysed the inter-
action between Med8p and any other Med8p
truncated derivative. This lack of interaction can-
not be attributed to a lack of expression, as all
GBD-Med8p fusion proteins were detected by
Western blotting using anti-GBD antibody (Figure
3(a)). As shown in Figure 2, GBD-Med8-C10p did
not interact with either Hxk2p or Med8p. The
deleted region of GBD-Med8-C10p contains the
serine/threonine-rich domain with several poten-
tial phosphorylation sites. These results indicate
that the interacting domain of Med8p includes the
C-terminal decapeptide and suggests that phos-
phorylation of this region could be involved in the
modulation of binding afﬁnity of the protein pairs.
A truncated Hxk2p (Hxk2-C70p), without 70
amino acid residues from the C-terminal end, was
fused to the Gal4p DNA-binding domain and
tested for interaction with Hxk2p and Med8p by
the two-hybrid assay in order to identify the
domain of Hxk2p that is important for interaction
with these proteins. We detected no interaction
between Hxk2–C70p and full-length Hxk2p or
Med8p (Figure 2). These results indicate that the
interacting domain of Hxk2p might include a
region contained in the 70 amino acid residues of
its C-terminal end. This lack of interaction cannot
be attributed to any lack of expression, as the
GBD-Hxk2-C70p fusion protein was detected by
Western blotting using anti-Hxk2p antibody
(Figure 3(b)).
In our efforts to understand the mode of action
of both the C-terminal decapeptide of Med8p and
the 70 amino acid residues of the C-terminal region
of Hxk2p we also tested for its direct interaction
with the full-length Med8p and Hxk2p. Our results
indicate that this is not the only region of inter-
action within Med8p and Hxk2p. The isolated pep-
tides no longer interacted in the two-hybrid system
(Figure 2). In this context it is puzzling that two-
hybrid GBD-constructs with smaller fragments
carrying only the C-terminal peptides of Med8p
and Hxk2p failed to interact with the full-length
proteins. This apparent discrepancy could be
caused by the artiﬁcial nature of the two-hybrid
system itself. Testing a fusion protein with only
the C-terminal part of Med8p or Hxk2p could
result in a misfolding of the Med8p and Hxk2p
interacting domains that destroys the protein
surface necessary for interaction.
AFM analysis of Med8p dimerization
Our results suggest that Med8p may form part of
a homodimer but these results do not show
whether the dimerization of the protein is required
for DNA binding. To provide an independent
assay we have used atomic force microscopy
(AFM) to image and map Med8p binding sites
within the HXT1 promoter.
A 538 bp DNA fragment of the HXT1 promoter
containing the consensus sequence of MED8 site
at 174 bp from one of the ends of the fragment
was used. The AFM images show most of the
Med8 protein free of any interaction with the
DNA but some of them appeared as Med8-HXT1
promoter complexes. Visualization of the 538 bp
DNA fragment complexed with Med8p by AFM
has demonstrated that Med8p coats a region of
the DNA molecules (Figure 4(b) and (c)) at a mean
position of 170 bp from one end. This result is
consistent with the protein binding to the DNA
Figure 3. Western blot analysis of Med8 and Hxk2
mutant proteins. (a) Expression of Med8 and truncated
versions of Med8p proteins fused with the GBD. Mono-
clonal antibody against Gal4p DNA-BD was used as
primary antibody, as described in Materials and
Methods. (b) Expression of Hxk2 and mutant Hxk2
proteins. The mutant Hxk2p, lacking 70 amino acid
residues from the C-terminal end, was fused to the GBD
and detected by using anti-Hxk2 polyclonal antibody.
The positions of molecular mass markers are indicated
at the left.
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detect unspeciﬁc Med8p binding to DNA, two
DNA fragments of the HXT1 promoter without
the Med8 site were used in control experiments.
Our results conﬁrmed that the Med8p–HXT1
promoter interaction is speciﬁc. The height of
Med8 interacting with the DNAwas also measured
with AFM. Figure 4(a) shows the histogram of the
height of the nucleoprotein complexes. The
measured height of Med8p interacting with the
DNA is a bimodal distribution with the most
probable heights sited at 1.7(^0.3) nm and
2.1(^0.3) nm. This result supports the idea that
this protein can bind to the Med8p binding
sequences present in the HXT1 promoter either as
a monomer or as a homodimer. It can be argued
that some of the complexes found are composed
of two unassociated monomers of Med8p binding
to the DNA. In that case the height measured
would coincide with the height measured for a
single molecule of Med8p binding. AFM does not
have high spatial resolution and in that case two
unassociated monomers or a just a single monomer
cannot be resolved if both heights are equal. On the
other hand, AFM is characterized by a high
resolution in the Z dimension. Our experiments
show two clear populations of complexes in terms
of height. Thus, we believe that Med8p interacts
with itself resulting in a homodimer with an effec-
tive height of 2.1(^0.3) nm. In Figure 4(b) and (c)
two AFM images of Med8–HXT1 complexes are
shown. In (b) the measured height (see inset) is
compatible with the protein binding as a monomer
and in (c) the height of the protein suggests that
Med8p is binding as a homodimer.
An alternative study with the DNA-unassociated
Med8 proteins was performed. In this case we
wanted to know whether Med8p homodimerizes
without interacting with the DNA. The AFM
study of the heights of the free Med8p revealed a
wide distribution of heights ranging from 1.0–
1.9 nm with two most probable heights at
1.3(^0.3) and 1.6(^0.3) nm (data not shown).
These values are compatible with the data from
the Med8p–DNA analysis if we add the measured
height of the DNA, which is 0.6(^0.1) nm. The
wide distribution indicates that structures are
more distorted when they are free of interaction
with the DNA than when they are interacting
with the DNA. However, the data of the protein
free of interaction with the DNA indicates that
this protein can also homodimerize.
Figure 4. AFM analysis of Med8p binding to HXT1
promoter. The heights of Med8p complexed with HXT1
are analysed and plotted as a histogram in (a). The
measured height of Med8p interacting with the DNA is
a bimodal distribution with the most probable heights
sited at 1.7(^0.3) nm and 2.1(^0.3) nm. (b) and (c) Two
nucleoprotein complexes. The proﬁle over the protein is
shown in the inset. The measured height of Med8p in
(b) is compatible with Med8p binding as a monomer
and the height measured in (c) with Med8 binding as a
homodimer.
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We sought to examine further the differential
binding activities observed in the yeast two-hybrid
system and to determine whether full-length
Med8p interacts with Hxk2p. To accomplish this
we performed glutathione-S-transferase (GST)
pull-down experiments with crude protein extracts
and a puriﬁed GST-Med8 fusion protein. As shown
in Figure 5(a), a strong retention of Hxk2 protein
was observed for samples containing GST-Med8p
and crude extracts from the wild-type yeast strain
DBY1315. When a control using crude extracts
from the double mutant strain DBY2052 (hxk1
hxk2) was performed to detect unspeciﬁc protein
binding to anti-Hxk2p antibody no signal was
observed.
To conﬁrm the interaction of Hxk2p with Med8p
under physiological conditions, we constructed a
yeast strain expressing an N-terminal HA-tagged
version of full-length Med8p. Whole-cell extracts
were prepared and immunoprecipitated with the
antibodies indicated in Figure 5(b). The resulting
immunoprecipitates were assayed for the presence
of Med8p by immunoblot analysis with anti-HA
antibodies. As shown in Figure 5(b), a strong and
speciﬁc signal of Med8p was observed for samples
immunoprecipitated with anti-Hxk2 antibody.
When an anti-Pho4 antibody or no antibody was
used to detect unspeciﬁc immunoprecipitation
and unspeciﬁc protein binding to anti-HA-Med8p
antibody, respectively, no signals were observed.
Thus, this interaction is dependent on the pro-
duction of exogenous HA-tagged Med8p as well
as anti-Hxk2p antibody.
We cannot exclude the possibility that some
unknown proteins might be present and could
mediate the interaction between Hxk2p and
Med8p. Therefore, we tried to show direct inter-
action of Med8p with Hxk2p by GST pull-down
assays with puriﬁed Hxk2 and Hxk2-C70 proteins
and the bacterially produced GST-Med8 fusion
protein. As shown in Figure 5(c), a strong and
speciﬁc retention of full-length Hxk2p was
observed for the sample containing GST-Med8p.
No retention was observed for the sample contain-
ing C-terminal truncated Hxk2-C70p.
Taken together, these results demonstrate that
full-length Hxk2p interacts directly with the full-
length Med8p in vivo and in vitro. In addition, a 70
amino acid residue C-terminal region of Hxk2p
and the Med8p C-terminal decapeptide are
required for Hxk2p–Med8p interaction.
Co-localization of Hxk2p and Med8p
To determine the biological signiﬁcance of the
interaction between Hxk2p and Med8p, we investi-
gated whether these two proteins co-localize in
DNA–protein complexes by gel-retardation
analyses. Therefore we tried to detect a differential
pattern of band shifts between Med8p and Med8p
together with Hxk2p with a fragment carrying the
MED8 site. The puriﬁed Med8 protein was exam-
ined in gel-mobility shift assays with
32P-labelled
MED8SUC2. As can be seen in Figure 6 (lane 3), a
protein–DNA complex (CI) was detected.
A speciﬁc binding of Med8p to the MED8SUC2
oligonucleotide was demonstrated by competition
assays with the corresponding non-labelled oligo-
nucleotide and with calf thymus DNA (data not
Figure 5. GST pull-down and immunoprecipitation
assays of the interaction Med8p–Hxk2p. (a) Med8p
co-precipitates together with Hxk2p from cell extracts.
Extracts from wild-type (WTE) (DBY1315, HXK1 HXK2)
(lane 1) and double mutant (DME) (DBY2050, Dhxk1
Dhxk2) strains (lane 2) were incubated with GST-Med8p
puriﬁed from E. coli on glutathione beads. Co-precipi-
tated proteins were separated by SDS-PAGE and visual-
ized on a Western blot with anti-Hxk2p antibody. (b) In
vivo co-immunoprecipitation of Med8p with Hxk2p.
S. cerevisiae Y187 cells were transformed with HA-tagged
GAD-Med8p. Cell extracts from the transformed Y187
wild-type strain (lane 1) were immunoprecipitated with
a polyclonal antibody to Pho4p (lane 2) or a polyclonal
antibody to Hxk2p (lane 3). Immunoprecipitates were
separated by SDS-10% PAGE and co-precipitated GAD-
Med8p was visualized on a Western blot with an anti-
HA antibody with the help of an HA tag present in the
GAD moiety. (c) Puriﬁed Hxk2p interacts with puriﬁed
Med8p. A GST-Hxk2 and a GST-Hxk2-C70 fusion protein
were puriﬁed on glutathione columns and incubated
with thrombin to isolate the native Hxk2 (lane 1) and
the Hxk2-C70 (lane 2) protein, respectively. Hxk2p was
incubated with puriﬁed GST protein on glutathione
beads (lane 3) and washed extensively. Both proteins,
Hxk2p (lane 4) or Hxk2-C70p (lane 5), were also incu-
bated with puriﬁed GST-Med8p on glutathione beads
and washed extensively. Co-precipitated proteins were
resolved on SDS-10% PAGE. The Hxk2 and Hxk2-C70
proteins were visualized on a Western blot with anti-
Hxk2 antibody.
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protein binding has previously been observed.
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Regarding the effect of Hxk2p on the formation of
the Med8p–MED8SUC2 complex, incorporation of
Hxk2p to the band shift reaction mixture shifted
the position of the CI Med8p–DNA complex
towards the top of the gel, to a complex (CII)
migrating more slowly (Figure 6, lane 4). A similar
result was observed when puriﬁed Hxk2p was
added to the band shift reaction mixture after the
Med8p–DNA complex was allowed to form (data
not shown). To conﬁrm that the CII complex was
caused by Hxk2p interaction with Med8p and not
by directly binding to DNA, we performed two
different band shift assays in order to: (i) directly
analyze DNA-binding activities of puriﬁed Hxk2p
and (ii) to study the effect of Hxk2-C70p (a trun-
cated derivative of Hxk2p not interacting with
Med8p) on the formation of the Med8p–MED8SUC2
complex. The Hxk2 protein did not bind the DNA
fragment and the Hxk2-C70p had no effect on the
pattern of band shifting observed with Med8p
(Figure 6, lanes 2 and 5). Moreover, the Hxk2-
C70p does not bind the DNA fragment (lane 6).
These results suggest that Hxk2p confers slow
mobility to CII by interaction with the Med8p com-
ponent of the nucleoprotein complex.
To analyse the role of the Med8p C-terminal
decapeptide on Med8p binding to the MED8 site,
we utilized the Med8-C10p truncated version of
Med8p to measure its afﬁnity for a DNA fragment
containing the optimal MED8 binding site. As can
be seen in Figure 6 (lane 7), the Med8-C10p binds
as efﬁciently as the wild-type Med8p. Regarding
the effect of Hxk2p and Hxk2-C70p on the for-
mation of the Med8-C10p-MED8SUC2 complex, the
incorporation of Hxk2p or Hxk2-C70p to the band
shift reaction mixture had no effect on the pattern
of band shifting observed with Med8-C10p alone
(Figure 6, lanes 8 and 9). This evidence suggests
that the Med8p C-terminal deletion does not
eliminate the DNA-binding activity but eliminates
the interaction with Hxk2p in the mutant Med8-
C10 protein.
Discussion
Here, we have carried out a molecular analysis
of the MED8 and HXK2 gene products. Several
results suggest that many genes controlled by
glucose induction and repression have Med8p
binding sites, with a consensus sequence of (C/A)
(G/A)(G/A)AAAT. The Med8p binds to the
MED8 site both as a monomer and in its homo-
dimeric state. A simple model considers Med8p as
a sphere. From Figure 4(a) the radius of the mono-
mer binding to the DNA is 1.7 nm. If the protein
appears as a dimer then the volume doubles and
the new radius of the sphere-shaped protein will
be 2.14 nm, which is in good agreement with the
value measured. Note that dehydration phenom-
ena, which are always present in AFM samples of
biological material when imaging in air, would
affect both monomer and dimer in the same
proportion, so the ratio between radii (dimer/
monomer) will not be affected.
We report evidence that Hxk2 and Med8 pro-
teins are physically associated. The most important
ﬁndings with regard to the mechanism of Hxk2p
action is that two-hybrid assays, co-precipitation
experiments, and gel-mobility shift analyses with
puriﬁed proteins involved in the glucose signalling
pathway of S. cerevisiae, demonstrated that full-
length Hxk2p interacts at its C-terminal region
directly with the amino acid region from 213 to
223 of Med8p. The association represents relatively
tight binding, as the complex survived co-precipi-
tation experiments under conditions of moderate
salt and detergent concentrations. Moreover, gel-
mobility shift assays suggest that these Hxk2p–
Med8p interactions are of physiological signiﬁ-
cance because they interact in a cluster with DNA
fragments containing the MED8 site.
These ﬁndings provide a molecular basis for
understanding the effect of Hxk2p on the glucose
signal transduction pathway of S. cerevisiae. Taking
into account that a Hxk2p–Med8p–DNA complex
seems to be required for inhibition of Med8p acti-
vating function by high levels of glucose, the
simple model consistent with both genetic and bio-
chemical evidences is that the nuclear Hxk2p
6
negatively affects the function of Med8p at glucose
Figure 6. Gel-mobility shift analysis of Med8p binding
to the MED8SUC2 regulatory region. Band shift experi-
ments were carried out as described in the legend to
Figure 1. Hxk2p and Hxk2-C70p were obtained, respect-
ively, from GST-Hxk2p and GST-Hxk2-C70p fusion
proteins coupled to glutathione-Sepharose beads by
site-speciﬁc separation of the GST afﬁnity tag using
2.5 units of thrombin. For the control lane 1 the radio-
labelled DNA fragment was added alone. F, Unbound
fragment; CI, position of shifted bands observed with
puriﬁed Med8p or Med8-C10p; CII, position of shifted
bands observed with puriﬁed Med8p and Hxk2p.
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complex with the mediator protein. This idea is
consistent with evidence suggesting that deletion
of the C-terminal decapeptide of Med8p results in
a truncated protein with residual function (DNA
binding) that is independent of Hxk2p interaction.
More complicated mechanisms of Hxk2p function
can also be imagined; for example, we cannot
exclude the possibility that Hxk2p activates or
interacts with a negative effector of Med8p.
In the presence of glucose the regulatory protein
Reg1p targets the protein phosphatase 1 (Glc7p),
to dephosphorylate serine 14 in Hxk2p
22 and the
equilibrium between the two isoforms of Hxk2p, a
monomer and a dimer
18 is shifted to the homo-
dimeric form.
19,20 In yeast cells grown in the
absence of glucose Hxk2p is phosphorylated at
serine 14
23 and displaces the equilibrium towards
the monomeric form. How the new conformation
of the phosphoenzyme may affect the fate of the
nuclear Hxk2p is unknown at the moment.
A plausible hypothesis could be that, in
derepressed cells the phosphorylated Hxk2p is
translocated to the cytosol, as happens with
Mig1p,
24 and the absence of nuclear Hxk2p causes
Med8p to function as a transcriptional activator by
correctly positioning the RNA polymerase II
holoenzyme transcriptional machinery.
Materials and Methods
Strains and growth media
Yeast two-hybrid experiments employed strain Y187
(MATa ura3-52 his3-200 ade2-101 trp1-901 leu2-3,112
gal4D gal80D URA3<GAL1UAS-GAL1TATA-lacZ). Co-pre-
cipitation experiments utilized yeast strains DBY1315
(MATa ura3-52 leu2-3,2-112 lys2-801 gal2) and DBY2052
(MATa hxk1<LEU2 hxk2-202 ura3-52 leu2-3,2-112 lys2-
801 gal2). Bacterial transformation and preparation of
recombinant plasmid DNA were performed in
Escherichia coli MC1061 (hsdR mcrB araD 139D(araABC-
leu)7679Dlacx74 galU galK rpsL thi). Fusion protein
expression was performed in E. coli BL21(DE3)pLysS
(Promega).
Yeast cells were grown in the following media: YEPD
(2% (w/v) glucose, 2% (w/v) Peptone, and 1% (w/v)
yeast extract), YEPE (3% (v/v) ethanol, 2% Peptone, and
1% yeast extract) and SD/ 2 Leu,Trp (2% glucose and
0.67% yeast nitrogen base without amino acids, sup-
plemented with all essential amino acids and nucleotides
except leucine and tryptophan). Amino acids and other
growth requirements were added at a ﬁnal concentration
of 20–150 mg/ml. The solid media contained 2% (w/v)
agar in addition to the components described above.
General DNA techniques
Routine DNA manipulations were essentially per-
formed as described.
25 The dideoxyribonucleotide chain
termination procedure was used for DNA sequencing
analysis.
26
Construction of plasmid DNAs
The plasmids used here are described in Table 1.
Hxk2p is numbered from residues 1 to 485
27,28 and the
Med8p is numbered from residues 1 to 223.
29 In both
cases, residue 1 is the initiator methionine in the primary
translation products. The plasmids carrying partial seg-
ments of a gene and the encoded products are named
according to the codons/amino acids that are retained
in the constructs. Plasmids pGBKT7-HXK2 and pACT2-
HXK2 carry, respectively, a 1455 bp EcoRI-BamHI and a
NcoI/BamHI fragment with the complete coding region
of the HXK2 gene in pGBKT7 (Clontech) and pACT2.
30
The HXK2 insert was synthesised by PCR using plasmid
pSP73-HXK2
8 as the template with the primer pairs
OL1 þ OL3 and OL2 þ OL3 (Table 2). Plasmids
pGBKT7-MED8 and pGADT7-MED8 carry a 669 bp
EcoRI-BamHI fragment with the complete coding region
of the MED8 gene in pGBKT7 and pGADT7 (Clontech).
The MED8 insert was synthesised by PCR using genomic
DNA as the template with the primer pairs OL4 þ OL5
(Table 2). To make plasmid pGBKT7-HXK2C70 a
1245 bp EcoRI-PstI fragment, obtained from pGBKT7-
HXK2, and carrying a 210 bp deletion in the 30 end of
HXK2 DNA was ﬁrst subcloned into the EcoRI and PstI
sites of pUK21 and then isolated as an EcoRI-SalI frag-
ment and ligated into the EcoRI and SalI sites of
pGBKT7. To make plasmid pGBKT7-C70HXK2 a 210 bp
PstI fragment, obtained from pGBKT7-HXK2, was
subcloned in the PstI site of pGBKT7. Plasmids
Table 1. Recombinant plasmids and encoded proteins
Plasmid Encoded product Source
pGBKT7/HXK2 Hxk2p
a This study
pGBKT7/MED8 Med8p
a This study
pGBKT7/HXK2-C70 Hxk2p without the C-terminal fragment (D
416-A
485)
a This study
pGBKT7-C70HXK2 C-terminal fragment (D
416-A
485) of Hxk2p
a This study
pGBKT7/MED8-C10 Med8p without the C-terminal fragment (T
214-N
223)
a This study
pGBKT7/MED8-C47 Med8p without the C-terminal fragment (S
177-N
223)
a This study
pGBKT7/MED8-C63 Med8p without the C-terminal fragment (T
161-N
223)
a This study
pGBKT7-C10MED8 C-terminal fragment (T
214-N
223) of Med8p
a This study
pACT2/HXK2 Hxk2p
b This study
pGADT7/MED8 Med8p
b This study
pGEX/HXK2 GST-Hxk2 fusion protein This study
pGEX/HXK2-C70 GST-Hxk2-C70 (D
416-A
485) fusion protein This study
PGEX/MED8 GST-Med8 fusion protein This study
a Fusion protein with the DNA-binding domain of Gal4p.
b Fusion protein with the activation domain of Gal4p.
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MED8C63 carry respectively 639 bp, 528 bp and 480 bp
BamHI-SalI fragments, with 30 bp, 141 bp and 189 bp
deletions at the 30 end of the MED8 gene, in pGBKT7.
The deleted MED8 DNA inserts were synthesised by
PCR using pGBKT7-MED8 plasmid as the template
with the primer pairs OL6 þ OL8, OL6 þ OL9 and
OL6 þ OL10 (Table 2). To make plasmid pGBKT7-
C10MED8, we reconstituted a 30 bp fragment in the 30 end
of the MED8 gene from two complementary oligonucleo-
tides OL11 þ OL12 (Table 2), with an added GATC
nucleotide overhang at the 50 end. The complementary
strands were annealed and subcloned in the BamHI site
of pGBKT7.
GST fusions vectors pGEX-HXK2, -HXK2C70 and
-MED8 were constructed as follow. Plasmids pGEX-
HXK2 and pGEX-HXK2C70 were constructed by sub-
cloning EcoRI-SalI fragments, obtained from plasmids
pGBKT7-HXK2 and pGBKT7-HXK2C70, respectively, in-
frame into the same sites of pGEX-4T (Amersham
Biosciences). Plasmid pGEX-MED8 carries a 669 bp
BamHI-EcoRI fragment with the complete coding region
of MED8 gene in pGEX-2T (Amersham Biosciences).
The MED8 insert was synthesised by PCR using genomic
DNA as the template with the primer pairs OL6 þ OL7
(Table 2). The DNA sequence of all PCR-generated con-
structs was veriﬁed by sequencing.
The GAD fusion plasmids were constructed in the
vectors pACT2 or pGADT7 and have an HA epitope tag
at the 50 end of the inserted DNA. The GBD fusion
plasmids were constructed in the vector pGBDKT7 and
have a c-Myc epitope tag at the 50 end of the inserted
DNA.
Yeast two-hybrid analysis
The yeast two-hybrid analysis
31 employed yeast
vectors pGADT7, pACT2 and pGBDKT7 and host strain
Y187 (described above) as supplied in the Matchmaker
two-hybrid system 3 from Clontech. The transformed
yeasts were grown in SD/ 2 Leu,Trp medium. Assays
for b-galactosidase activity followed protocols described
elsewhere.
25 Qualitative assessment of expression from
the lacZ reporter gene was made using X-gal as a
chromogenic substrate for b-galactosidase in a colony-
lift ﬁlter assay. For quantitative determination of
b-galactosidase activity, the absorbance at 420 nm of
o-nitrophenol released from the substrate o-nitrophenyl
b-D-galactopyranoside was normalized to total protein
and is reported as m-units/mg of protein. Expression
levels of the GAD and GBD fusion proteins were con-
trolled by Western blot analysis. Experiments were per-
formed a minimum of three times. Values shown are
representative results from individual experiments.
AFM sample preparation and AFM imaging
Sample preparation for atomic force microscopy
(AFM)
32 (also called scanning force microscopy) and the
method of AFM imaging have been described.
33
Antibodies and immunological methods
GBD and GAD fusion proteins were detected using
Gal4p DNA-BD monoclonal antibodies and HA-tag
polyclonal antibodies, respectively. Native and recombi-
nant Hxk2p were detected using polyclonal antibodies
raised against Hxk2p.
8
Immunoprecipitation experiments were performed by
using whole-cell extracts prepared as reported.
6 Extracts
were incubated with anti-Hxk2p for one hour at 4 8C.
Protein A-Sepharose beads (Amersham Biosciences)
were then added and incubated for one hour at 4 8C.
After extensive washes with Staph A buffer (150 mM
NaCl, 101 mM Na2HPO4, 18 mM NaH2PO4 (pH 7.3),
20% (v/v) Triton X-100, 1% (w/v) SDS, 5% (w/v) deoxy-
cholate), immunoprecipitated samples were boiled in
SDS-loading buffer. The supernatant was subjected to
SDS/12% polyacrylamide gel electrophoresis (SDS-
PAGE) and detected by Western blot using anti-HA anti-
body and horseradish peroxidase-conjugated protein-A
by the ECL system (Amersham Biosciences).
Western blot analysis was performed by using yeast
transformed cells containing appropriate plasmids.
Yeast crude extracts were prepared as follows: yeast
was grown on 10 to 20 ml of rich medium (YEPD) at
28 8C until an absorbance at 600 nm of 1.0. Cells were
collected, washed twice with 1 ml of 1 M sorbitol and
suspended in 100 ml of 50 mM Tris–HCl (pH 7.5) buffer
containing 0.2 mM EDTA, 0.5 mM dithiothreitol (DTT),
0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF), 0.42 M
NaCl and 1.5 mM MgCl2. The cells were broken by vor-
texing (6 £ 20 seconds) in the presence of glass beads
(0.5 g), and 400 ml of the same buffer were added to the
suspension. After centrifugation at 19,000g (14,000 rpm)
for 15 minutes at 4 8C, the supernatant was used as
crude protein extract. Proteins were transferred to
enhanced chemiluminescence nitrocellulose membrane
(Amersham Biosciences), which was then incubated
Table 2. Oligonucleotide primers for PCR
Primer Sequence (50 ! 30) Gene location Restriction sites for cloning
OL1 TAGAATTCATGGTTCATTTAGGTCCAAAA HXK2; þ1t oþ21 EcoRI
OL2 TACCATGGTTCATTTAGGTCCAAAAA HXK2; þ1t oþ22 NcoI
OL3 ATGGATCCAGCACCGATGATACCAAC HXK2; þ1437 to þ1455
a BamHI
OL4 GCGGAATTCATGTCACAATCTACTGCATC MED8; þ1t oþ20 EcoRI
OL5 AAGGATCCGCATTACTAGATGATGTTGA MED8; þ648 to þ669
a BamHI
OL6 ATGGATCCTCATGTCACAATCTACTGC MED8; þ1t oþ17 BamHI
OL7 GCGAATTCAATTACTAGATGATGTTGA MED8; þ648 to þ669
a EcoRI
OL8 ATAGTCGACTCAAATAATGGGCTTTTCCC MED8; þ622 to þ639
a SalI
OL9 ATAGTCGACTCATTCTTCATTTTTGAAATC MED8; þ510 to þ528
a SalI
OL10 ATAGTCGACTCAGCGCGCCCAATTCGTTA MED8; þ463 to þ480
a SalI
OL11 GATCATTACTAGATGATGTTGAAGTAGATCCCGT MED8; þ638 to þ669
OL12 GATCACGGGATCTACTTCAACATCATCTAGTAAT MED8; þ638 to þ669
a
a Complementary strand.
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DNA fragment Sense Antisense
MED8HXT1 tcgaACTAGGAAGAAATGCTGCAGGGCA (2369) tcgaTGCCCTGCAGCATTTCTTCCTAGT (2392)
MED8HXK1 tcgaGACCTAAGAACTATGCATTTTTTTTTAAGGG (2334) tcgaCCCTTAAAAAAAAATGCATAGTTCTTAGGTC (2364)
MED8GLK1 tcgaCAAGAAAATGCACGCGTAACAAAATATATATATATATA (2526) tcgaTATATATATATATATTTTGTTACGCGTGCATTTTCTTG (2541)with an anti-HA antibody or with anti-Hxk2p polyclonal
antibody. Horseradish peroxidase-conjugated protein-A
was used as secondary reactant. The complex was
detected by the ECL detection system (Amersham
Biosciences).
GST pull-down experiments
GST fusion protein expression vectors (pGEX-HXK2,
-HXK2-C70 and -MED8) were transformed into E. coli
strain BL21(DE3). Cells were grown to A600 0.5–0.8,
induced with 0.5 mM isopropyl-1-thio-b-D-galacto-
pyranoside at 37 8C for three hours, and collected by
centrifugation. Cell pellets were resuspended in PBS
buffer (150 mM NaCl, 101 mM Na2HPO4,1 8 m M
NaH2PO4, pH 7.3) and sonicated. Insoluble material was
removed by centrifugation (17,000g for 20 minutes at
4 8C). Soluble extracts were incubated with glutathione-
Sepharose 4B (Amersham Biosciences) for one hour at
4 8C, washed extensively with PBS buffer and
resuspended in the same buffer. The GST-Med8, GST-
Hxk2 and GST-Hxk2C70 fusion proteins coupled to
glutathione-Sepharose beads were incubated with
2.5 units of thrombin (two hours at 4 8C) for site-speciﬁc
separation of the GST afﬁnity tag from Med8, Hxk2 and
Hxk2C70 proteins. Equal amounts of GST and GST-
Med8p coupled to glutathione-Sepharose beads were
incubated with Hxk2 and Hxk2C70 puriﬁed proteins or
yeast whole-cell extracts for one hour at 4 8C in PBS
buffer. Beads were gently washed ﬁve times with 2.5 ml
of PBS buffer, boiled in 25 ml of sample-loading buffer
(50 mM Tris–HCl (pH 6.8), 100 mM DTT, 2% SDS, 0.1%
bromophenol blue, 10% glycerol), and analysed by SDS-
PAGE followed by Western blot using anti-HA or anti-
Hxk2p antibodies and horseradish peroxidase-
conjugated protein-A. Bound antibodies were detected
using the ECL system (Amersham Pharmacia Biotech).
DNA probes
To investigate interaction of Med8p with the
sequences carrying regulatory elements in the GLK1,
HXK1 and SUC2 promoter regions we reconstituted the
fragment from two complementary oligonucleotides.
The complementary strands were annealed and either
end was labelled with [a-
32P]dCTP by ﬁll-in, using the
Klenow fragment of DNA polymerase I. The labelled
double-stranded DNA was used as probe and the
unlabelled was used as competitor in gel retardation
assays. In all cases the oligonucleotides were synthesised
with an added TCGA nucleotide overhang at the 50-
terminal end. The synthetic DNA fragments used in gel
retardation experiments are listed in Table 3.
Gel retardation assays
Binding reactions contained 10 mM Hepes (pH 7.5),
1 mM DTT, 1 to 5 mg of poly(dI-dC) and 0.5 ng of end-
labelled DNA in a volume of 25 ml. When unlabelled
competitor DNA was added, its amount was 20 ng. The
binding reaction mixtures included 3 mg( 6 ml) of the
corresponding puriﬁed protein and after 30 minutes of
incubation at room temperature they were loaded onto
non-denaturing 4% polyacrylamide gels. Electrophoresis
was carried out at 10 V/cm of gel for 45 minutes to one
hour in 0.5 £ TBE buffer (45 mM Tris–borate, 1 mM
EDTA). Gels were dried and autoradiographed at
270 8C with an intensifying screen.
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